Literature DB >> 7905496

Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection.

S C Morris1, K B Madden, J J Adamovicz, W C Gause, B R Hubbard, M K Gately, F D Finkelman.   

Abstract

The effects of murine rIL-12 on cytokine gene expression and Ig secretion were studied in vivo. In untreated mice IL-12 enhanced IFN-gamma and IL-10 gene expression and protein secretion, reduced base line IL-3 and IL-4 gene expression, and increased serum IgG2a concentration. In mice that had been injected with goat anti-mouse IgD antibody (G alpha M delta) to induce increases in IL-3, IL-4, and IL-10 gene expression and serum IgE, IgG1, IgG2a, and IgG3 concentrations, the simultaneous injection of IL-12 enhanced IFN-gamma and IL-10 gene expression and suppressed IL-3 and IL-4 gene expression and serum IgG and IgE responses. Anti-IFN-gamma mAb neutralized most, but not all, IFN-gamma produced by mice treated with G alpha M delta and IL-12. Anti-IFN-gamma mAb enhanced IL-3 and IL-4 gene expression, did not affect IL-10 or IFN-gamma gene expression, and increased serum IgG1, IgG2a, and IgG3 levels, but had relatively little effect on serum IgE in these mice. In contrast to its effects in G alpha M delta-treated mice, IL-12 failed to inhibit the IgE response to G alpha M epsilon antibody, which stimulates mIgE+ B cells to secrete IgE. These observations demonstrate that: 1) IL-12 may limit its own effects by inducing the production of a cytokine (IL-10) that down-regulates both IL-12 production and IL-12-induced IFN-gamma production; 2) IL-12 inhibits the production of at least one cytokine, IL-3, that is not generally regarded to be strictly Th1- or Th2-associated; 3) IL-12 inhibits switching to IgE secretion to a greater extent than it inhibits switching to other Ig isotypes; and 4) the in vivo effects of IL-12 are, to a large extent, IFN-gamma-dependent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905496

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge.

Authors:  R D Bungiro; M Goldberg; P K Suri; P M Knopf
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response.

Authors:  L R Schopf; J L Bliss; L M Lavigne; C L Chung; S F Wolf; J P Sypek
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis.

Authors:  S A Fulton; J M Johnsen; S F Wolf; D S Sieburth; W H Boom
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

4.  The roles of tumour necrosis factor-alpha, interleukin-1 and interleukin-12 in murine cytomegalovirus infection.

Authors:  S T Yerkovich; S D Olver; J C Lenzo; C D Peacock; P Price
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

5.  Clinical chorioamnionitis at term II: the intra-amniotic inflammatory response.

Authors:  Roberto Romero; Piya Chaemsaithong; Steven J Korzeniewski; Adi L Tarca; Gaurav Bhatti; Zhonghui Xu; Juan P Kusanovic; Zhong Dong; Nikolina Docheva; Alicia Martinez-Varea; Bo Hyun Yoon; Sonia S Hassan; Tinnakorn Chaiworapongsa; Lami Yeo
Journal:  J Perinat Med       Date:  2016-01       Impact factor: 1.901

6.  Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease.

Authors:  R G Titus; G K DeKrey; R V Morris; M B Soares
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

7.  Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major.

Authors:  Z E Wang; S Zheng; D B Corry; D K Dalton; R A Seder; S L Reiner; R M Locksley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.

Authors:  Willy K Tonui; J Santiago Mejia; Lisa Hochberg; M Lamine Mbow; Jeffrey R Ryan; Adeline S T Chan; Samuel K Martin; Richard G Titus
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.

Authors:  S Gurunathan; K R Irvine; C Y Wu; J I Cohen; E Thomas; C Prussin; N P Restifo; R A Seder
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

10.  Modulation of an interleukin-12 and gamma interferon synergistic feedback regulatory cycle of T-cell and monocyte cocultures by Porphyromonas gingivalis lipopolysaccharide in the absence or presence of cysteine proteinases.

Authors:  Peter L W Yun; Arthur A DeCarlo; Charles Collyer; Neil Hunter
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.